Aligos Therapeutics
Follow-up to the original 4-part deep dive (Oct 2025). New data, new deals, new catalysts — and the stock is cheaper. It's been almost a year since I published the 4-part ALGS deep dive. Back then, Aligos was trading around $10 with $123M in cash — a
AI
The weekly scanner is back. I paused publication of catalyst scanner since end of August to rebuild the system. This is the first edition powered by BioStockInfo’s own catalyst calendar, which I’ve developed to make upcoming biotech events easier to track and check, and available for free for
In January I shorted the ALMS overnight gap ahead of the ONWARD psoriasis readout and got slaughtered when envudeucitinib posted best-in-class PASI 100 numbers (my January piece). Eight months later the stock has round-tripped for the opposite reason. On September 1 the Phase 2b LUMUS trial in
Catalyst Calendar
The BioStockInfo Catalyst Calendar is live at app.biostockinfo.com: free, no sign-up, built only from what companies say in their own SEC filings.
AI
September is going to be loud. Nine of the twenty names below carry a Q3 window that has not yet closed, and almost all of them land in the same four-week stretch: uniQure's four-year Huntington's data and BLA, Immix's registrational CAR-T
AI
The list turned over almost completely this week. Only Karyopharm and Longeveron survive from last week's featured ten; Protagonist, Pyxis and Tyra climb up from the watchlist. That is what happens when a month's worth of "Aug 2026 (Est.)" windows either resolve or expire
What this is, and what it is not. This review does not — and is not intended to — show that the BSI AI Catalyst Scanner is a reliable tool to be used on its own for investment decision-making. It is one input in a research process. Everything below is a
AI
Six of this week's ten featured names were in last week's report. That is not the scanner being lazy — it is what an August calendar looks like when a dozen companies all guided to "mid-2026" and the quarter is running out of days.
AI
The top of this week's list is a wreckage report. Karyopharm ($KPTI) takes the #1 slot down 80% on the month after a Phase 3 miss on July 30. Capricor ($CAPR) sits at #5 down 83% after an FDA advisory committee voted 9–3 against its drug on
Finding Undervalued Biotechs via Thorough Investigation and Sharing Tips
The tape going into August is a study in exhaustion. Look down this week's featured list and the striking thing isn't the catalysts — it's how many of these names are trading like the market has already given up on them. Beam sits at an
Programming note — the weekly AI Catalyst Scanner will run through the end of August 2026, then pause. The economics of the weekly format have moved against it: the API and data costs behind each issue have risen steadily, and the honest reason we're not converting this into a
This week's screen is dominated by a late-July-through-August PDUFA pileup — nine of ten featured names have FDA decisions or major data landing inside the next six weeks, and five of those cluster in a five-day stretch between July 26 and August 5. That'
In vivo CAR-T just became biotech's hottest autoimmune bet: $14B committed, zero human readouts. We break down all four B-cell depletion modalities, the leaders, the risks, and what's buyable.
This issue skews toward hard regulatory dates and, unusually, toward big pharma. Eight of the seventeen names carry a PDUFA or generic-drug action date, clustered between July 11 and August 17 — Celcuity, Capricor, Outlook, MannKind, NRx, Moderna, Merck, and Astellas all have the FDA calendar circled. That's
Disclosure: I hold a bullish position in Altimmune (ALT) through call options expiring January 2027 — a leveraged, directional position that profits if the stock rises. Assume that gives me a financial interest in a favorable outcome and weigh this analysis accordingly. My positions may change at any time without notice.
This week's slate is short, and the reason is mechanical rather than a lack of opportunity. The scanner only surfaces catalysts dated at least seven days forward from the scan date, and no more than 45 days out — a 7-to-45-day forward window. Anything with a
The XBI spent the back half of June grinding sideways after a sharp spring rally, and this week's scan reflects a tape that's rewarding regulatory clarity over clinical hope. The top of the board is unusually de-risked: the two highest-ranked names are sitting on
This week the tape, not the calendar, sets the mood. Almost every name on the featured board walks into its catalyst beaten down — RSIs clustered in the teens to mid-40s, twenty-one-day momentum negative across nine of the top ten. Celcuity is the sharpest example: a company with
The calendar does the heavy lifting this week. ENDO, EHA and the tail of ASCO converge in mid-June, stacking the kind of conference readouts that move small-cap biotech regardless of where the broad tape sits. Three of this week's featured names — Rezolute, MBX and Cellectis — present
The first PROTAC just got approved. Here's the science behind protein degradation, the money pouring in, the rival approaches, and the biotechs worth watching.
(Editor's note) I sincerely apologize for a data discrepancy in last week's scanner article, where information regarding BCAB and BCYC was inadvertently conflated. While the core ML/AI data sources remain accurate and unchanged, a temporary switch in my editorial processing tools caused a degradation in
